Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 9/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.56 |
| ▸ | HTR1E | P28566 | 2/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20202491 | 0.99 | CHRM3 (1.00) | CHRM3CHRM1HTR1ES1PR3MEN1 | |
| SCHEMBL18199755 | 0.96 | CHRM3 (1.00) | CHRM3CHRM1HTR1ES1PR3MEN1 | |
| SCHEMBL15127557 | 0.85 | CHRM3 (0.74) | CHRM3HTR1ES1PR3MEN1LMNA | |
| SCHEMBL27933777 | 0.84 | CHRM3 (0.72) | CHRM3HTR1ES1PR3MEN1LMNA | |
| SCHEMBL20412693 | 0.83 | CHRM3 (0.71) | CHRM3CHRM1HSD17B10 | |
| SCHEMBL11084994 | 0.82 | CHRM3 (0.70) | CHRM3HTR1ES1PR3MEN1LMNA | |
| SCHEMBL3636177 | 0.82 | CHRM3 (0.69) | CHRM3CHRM1HTR1ES1PR3MEN1 | |
| SCHEMBL18199753 | 0.81 | CHRM3 (1.00) | CHRM3MEN1KMT2A | |
| SCHEMBL11083565 | 0.81 | CHRM3 (0.71) | CHRM3HTR1ES1PR3MEN1LMNA | |
| SCHEMBL18199751 | 0.81 | CHRM3 (1.00) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3288926-B1 | N-ARALKYLCARBONYL-PIPERAZINE AND -HOMOPIPERAZINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | UNILEVER PLC (GB) | 2021-01-20 | — | — | EP | disclosed |
| US-20180148425-A1 | N-ARALKYLCARBONYL-PIPERAZINE AND -HOMOPIPERAZINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | CONOPCO, INC., D/B/A UNILEVER (US) | 2018-05-31 | — | — | US | disclosed |
| US-20180148425-A1 | N-ARALKYLCARBONYL-PIPERAZINE AND -HOMOPIPERAZINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | CONOPCO, INC., D/B/A UNILEVER (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148425-A1 | N-ARALKYLCARBONYL-PIPERAZINE AND -HOMOPIPERAZINE COMPOUNDS AND PERSONAL CARE COMPOSITIONS COMPRISING THE SAME | MKI67, CUTA, PLP2 | CHRM3 3141/4885CHRM1 3549/4885HTR1E 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.